Sitagliptin 100 mg

DRUG17 trials

Sponsors

University of British Columbia, Amsterdam UMC, location VUmc, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Merck Sharp & Dohme LLC, Janssen Research & Development, LLC

Conditions

Beta-cell FunctionBone Loss, PostmenopausalDiabetes MellitusDiabetes Mellitus Type 2Diabetes Mellitus, Type 2Diabetes, Type 2Glucocorticoid-induced DiabetesHyperglycemia

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (Explores What the Body Does to the Drug), and Pharmacodynamics (Explores What a Drug Does to the Body) of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

CompletedNCT00871507

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Diabetes Mellitus, Type 2

Start: 2009-04-30End: 2009-07-31Updated: 2014-05-22

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin

CompletedNCT01054118

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Diabetes Mellitus, Type 2

Start: 2009-12-31End: 2010-02-28Updated: 2013-09-04

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

CompletedNCT01582308

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2012-06-21End: 2012-12-14Updated: 2017-05-30

Phase 2

Sitagliptin in the Elderly

CompletedNCT00451113

University of British ColumbiaType 2 Diabetes

Start: 2006-11-30End: 2012-11-30Updated: 2018-01-18

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

CompletedNCT01059825

Merck Sharp & Dohme LLCDiabetes Mellitus, Type 2

Start: 2010-02-24End: 2011-01-20Updated: 2018-09-13

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

CompletedNCT01336738

PfizerDiabetes, Type 2

Start: 2011-06-30End: 2012-03-31Updated: 2013-08-06

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

CompletedNCT01338870

PfizerDiabetes Mellitus, Type 2

Start: 2011-06-30End: 2012-03-31Updated: 2013-04-23

Add Glucokinase Activator to Target A1c

CompletedNCT02405260

vTv TherapeuticsDiabetes Mellitus, Type 2

Start: 2015-03-31End: 2016-09-30Updated: 2017-02-10

12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin

CompletedNCT02647320

Daiichi SankyoType 2 Diabetes Mellitus

Start: 2016-01-31End: 2017-01-31Updated: 2019-02-25

Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

CompletedNCT03359590

Profil Institut für Stoffwechselforschung GmbHPharmacological Action

Start: 2018-03-21End: 2019-07-17Updated: 2021-02-21

Phase 3

Safety and Efficacy of Co-Administration of Sitagliptin and Metformin in China (MK-0431-121)

CompletedNCT01076088

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2010-11-15End: 2012-12-24Updated: 2017-05-23

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

CompletedNCT01137812

Janssen Research & Development, LLCDiabetes Mellitus, Type 2

Start: 2010-07-31End: 2012-03-31Updated: 2015-01-15

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

CompletedNCT02099110

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2014-04-22End: 2016-05-26Updated: 2018-09-12

DPP4-Inhibitors and Bone Metabolism in Diabetes

CompletedNCT06770894

Azienda Policlinico Umberto IBone Loss, Postmenopausal, Diabetes Mellitus Type 2, Osteoporosis

Start: 2019-09-24End: 2024-01-24Updated: 2025-01-13

Phase 4

An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

CompletedNCT03267576

Janssen Research & Development, LLCDiabetes Mellitus, Type 2

Start: 2017-10-27End: 2018-10-01Updated: 2019-11-29

Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors

Not yet recruitingNCT07108985

Yonsei UniversityDiabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance

Start: 2025-09-30End: 2030-08-31Target: 100Updated: 2025-08-07

Unknown Phase

Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome

CompletedNCT00721552

Amsterdam UMC, location VUmcBeta-cell Function, Diabetes Mellitus, Glucocorticoid-induced Diabetes +1

Start: 2008-10-31End: 2012-06-30Updated: 2012-07-02

Related Papers

Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial.

2025-10-14

The effects of ertugliflozin on β‐cell function: Pooled analysis from four phase 3 randomized controlled studies

Diabetes Obesity and Metabolism2020-07-236 citations

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials

Diabetes Therapy2020-07-0914 citations

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.

2020-05-0518 citations

Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus

Current Medical Research and Opinion2020-04-2310 citations

Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus

Current Medical Research and Opinion2020-04-233 citations

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.

2020-01-039 citations

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.

2018-01-25118 citations

Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials

Patient2018-01-0810 citations

Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis

Current Medical Research and Opinion2016-12-1932 citations

Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes

Postgraduate Medicine2016-07-0814 citations

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America

Current Medical Research and Opinion2015-11-1810 citations

Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.

2015-03-189 citations

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.

2014-03-0193 citations

Postprandial microvascular function deteriorates in parallel with gradual worsening of insulin sensitivity and glucose tolerance in men with the metabolic syndrome or type 2 diabetes.

2012-11-2410 citations